復星醫藥(600196.SH):子公司聯合注射用曲妥珠單抗聯合化療(XELOX)啟動II期臨牀研究
格隆匯9月30日丨復星醫藥(600196.SH)公佈,近日,公司控股子公司上海復宏漢霖生物技術股份有限公司(“復宏漢霖”)於中國境內(不包括港澳台地區,下同)就HLX22(抗人表皮生長因子受體-2的人源化單克隆抗體注射液,擬用於胃癌和乳腺癌治療)聯合注射用曲妥珠單抗(商品名:漢曲優®)聯合化療(XELOX)(以下簡稱“該治療方案”)用於一線治療HER2陽性的局部晚期/轉移性胃癌(GC)啟動II期臨牀研究。
該治療方案主要用於治療胃癌;截至本公吿日,於中國境內尚無同類用於治療胃癌的聯合用藥治療方案獲國家藥品監督管理局上市批准。
截至2021年8月,集團現階段針對HLX22聯合注射用曲妥珠單抗聯合化療的累計研發投入為人民幣459萬元(未經審計;不包含單藥)。
HLX22(單藥)為復宏漢霖自AbClon,Inc.許可引進,並後續自主研發的創新型治療用生物製品,擬用於胃癌和乳腺癌治療。截至公吿日,HLX22(單藥)的研究情況處於中國境內處於I期臨牀試驗中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.